Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licogliflozin in obese patients with NASH
NCT03205150Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Alanine Aminotransferase at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03205150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205150.